KemPharm Inc. (KMPH) Downgraded by Zacks Investment Research to Hold
KemPharm Inc. (NASDAQ:KMPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday.
According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. “
A number of other research analysts have also recently issued reports on the stock. Oppenheimer Holdings Inc. reissued a “buy” rating and issued a $11.00 price objective on shares of KemPharm in a research note on Tuesday, June 14th. Canaccord Genuity reissued a “buy” rating on shares of KemPharm in a research note on Wednesday, August 10th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/kempharm-inc-kmph-downgraded-by-zacks-investment-research-to-hold.html
Shares of KemPharm (NASDAQ:KMPH) opened at 4.79 on Wednesday. KemPharm has a 12-month low of $3.52 and a 12-month high of $21.30. The firm’s 50-day moving average price is $4.63 and its 200-day moving average price is $7.47. The firm’s market capitalization is $70.15 million.
KemPharm (NASDAQ:KMPH) last announced its quarterly earnings data on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.36. Equities analysts predict that KemPharm will post ($1.78) earnings per share for the current fiscal year.
In related news, EVP Daniel L. Cohen bought 10,000 shares of the business’s stock in a transaction on Tuesday, September 6th. The shares were purchased at an average price of $4.75 per share, for a total transaction of $47,500.00. Following the completion of the transaction, the executive vice president now directly owns 1,310 shares of the company’s stock, valued at approximately $6,222.50. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 22.80% of the stock is currently owned by company insiders.
A number of hedge funds have recently modified their holdings of the stock. Menta Capital LLC raised its stake in shares of KemPharm by 11.3% in the first quarter. Menta Capital LLC now owns 11,410 shares of the specialty pharmaceutical company’s stock worth $165,000 after buying an additional 1,154 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in shares of KemPharm by 4.9% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 35,485 shares of the specialty pharmaceutical company’s stock worth $515,000 after buying an additional 1,653 shares in the last quarter. Kennedy Capital Management Inc. raised its stake in shares of KemPharm by 10.4% in the first quarter. Kennedy Capital Management Inc. now owns 55,126 shares of the specialty pharmaceutical company’s stock worth $799,000 after buying an additional 5,211 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of KemPharm by 3.4% in the second quarter. Vanguard Group Inc. now owns 318,210 shares of the specialty pharmaceutical company’s stock worth $1,267,000 after buying an additional 10,390 shares in the last quarter. Finally, William Harris Investors Inc. raised its stake in shares of KemPharm by 93.3% in the second quarter. William Harris Investors Inc. now owns 30,891 shares of the specialty pharmaceutical company’s stock worth $123,000 after buying an additional 14,911 shares in the last quarter. Hedge funds and other institutional investors own 42.65% of the company’s stock.
KemPharm Company Profile
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related companies with MarketBeat.com's FREE daily email newsletter.